OSBPL7-IN-1 是一种具有口服活性的氧甾醇结合蛋白样 7 (OSBPL7) 抑制剂。OSBPL7-IN-1 促进质膜上 ABCA1 的增加而不影响 mRNA 表达。
OSBPL7-IN-1 is an orally active oxysterol binding protein like 7 (OSBPL7) inhibitor. OSBPL7-IN-1 promotes an increase of ABCA1 at the plasma membrane without affecting mRNA expression[1].
OSBPL7-IN-1 (compound G or Cpd G; 1-10 µM) increase plasma membrane ATP-binding cassette transporter (ABCA1) in cultured human podocytes, and significantly increase ABCA1-dependent cholesterol efflux[1].
OSBPL7-IN-1 (100 mg/kg; oral gavage; daily; for 28 days) treatment normalizes proteinuria and prevents renal function decline in mouse models of proteinuric kidney disease[1].
[1]. Matthew B Wright, et al. Compounds targeting OSBPL7 increase ABCA1-dependent cholesterol efflux preserving kidney function in two models of kidney disease. Nat Commun. 2021 Aug 2;12(1):4662.
动态评分
0.0